Jones Kenneth T. - 12 Sep 2023 Form 4 Insider Report for Zynerba Pharmaceuticals, Inc.

Role: Vice President, Corporate Controller and Interim Chief Financial Officer
Signature: /s/ Albert P. Parker, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 12 Sep 2023
Net transactions value: -$3,321
Form type: 4
Filing time: 14 Sep 2023, 16:13:21 UTC
Previous filing: 15 Aug 2023
Next filing: 11 Oct 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZYNE	Common Stock	Award		+9,000	+11%		88,025	12 Sep 2023	Direct	F1
transaction	ZYNE	Common Stock	Sale	$3,321	-2,505	-2.8%	$1.33	85,520	13 Sep 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 9,000 performance-based restricted stock awards granted in a prior year.
F2	This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.

Remarks:

Vice President, Corporate Controller and Interim Chief Financial Officer